Business
Medicenna to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
TORONTO and HOUSTON, April 22, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (&...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"Medicenna to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference\n\n\n\n TORONTO and HOUSTON, April 22, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, today announced that Dr. Fahar Merchant, President and CEO of Medicenna, will present and participate in one-on-one meetings at the 2025 Bloom Burton & Co. Healthcare Investor Conference being held in Toronto on May 5-6, 2025.\n \n\n Details on the presentation are as follows:\n \n\n\n Date:\n \n Monday, May 5, 2025\n \n\n Time:\n \n 2:30 p.m. Eastern Time\n \n\n Location:\n \n Metro Toronto Convention Centre, Toronto\n \n\n Webcast:\n \n\n https://event.summitcast.com/view/hG2KhRan38C8o5wZiWyxNK/6hRWPTiDpf8iZLFakhbeJ6\n \n\n\n Webcast and replay information for this event will also be available on the Investor Relations section of Medicenna's website at\n \n ir.medicenna.com\n \n . The replay will be available for 90 days.\n \n\n The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from premier Canadian publicly traded and private companies through presentations and private meetings. For more information, please visit:\n \n bloomburton.com/conference\n \n .\n \n\n\n About Medicenna Therapeutics\n \n\n\n Medicenna is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Medicenna’s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Medicenna’s IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied in 5 clinical trials enrolling over 130 patients, including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug sta...